安进Teprotumumab在华申报临床

Investment Rating - The report does not provide specific ratings for the chemical pharmaceuticals and traditional Chinese medicine sectors, while the biopharmaceutical sector is rated as neutral [1][2]. Core Insights - The pharmaceutical sector has shown a market performance increase of +2.18% as of November 5, 2024, underperforming the CSI 300 index by 0.35 percentage points, ranking 18th among 31 sub-industries. The best-performing sub-industries include medical research outsourcing (+4.31%), hospitals (+4.06%), and vaccines (+2.97%), while offline pharmacies (-0.40%), pharmaceutical distribution (+1.61%), and medical consumables (+1.95%) lagged behind [2][3]. - Notable individual stock performances include Haobor (+20.01%), Haoyuan Pharmaceutical (+14.73%), and Nossger (+14.35%) leading in daily gains, while Huitai Medical (-3.70%), Kangwei Century (-3.65%), and Jiu'ao Pharmaceutical (-3.00%) experienced the largest declines [2][3]. Summary by Sections Industry News - On November 5, 2024, the CDE announced the acceptance of a new drug clinical trial application for Teprotumumab, a drug developed by Amgen and Horizon, which was first approved by the FDA in January 2020 for the treatment of thyroid eye disease [3]. Company News - Various companies have received approvals for their products, including: - Cangyi Pharmaceutical's subsidiary received approval for Winpai Dexamethasone Injection [3]. - Jincheng Pharmaceutical's subsidiary received approval for Cefoperazone Dry Suspension [3]. - Baiyunshan's subsidiary received approval for Cefotaxime Dispersible Tablets [3]. - Yahui Pharmaceutical received approval for APL-1706 for bladder cancer [3].